WIN 55,212-2
Appearance
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
![]() ![]() |
![](http://upload.wikimedia.org/wikipedia/commons/thumb/e/e0/Pancreatic_stellate_cell_cropped.png/220px-Pancreatic_stellate_cell_cropped.png)
WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure.[3][4][5]
WIN 55,212-2 is a potent cannabinoid
MAP kinase via receptor-mediated signaling.[9]
At 5 μM WIN 55,212-2 inhibits
CB1 receptor-dependent fashion.[10]
WIN 55,212-2, along with
markers. This anti-inflammatory action is induced through agonist action at cannabinoid receptors, which prevents microglial
activation that elicits the inflammation.
WIN 55,212-2 is a full agonist at the
CB1 cannabinoid receptor (Ki = 1.9 nM) and has much higher affinity than THC (Ki = 41 nM) for this receptor.[11] WIN 55,212-2 is also an agonist of the PPARα and PPARγ nuclear receptors.[12]
WIN 55,212-2 reduces voluntary wheel running in laboratory mice, but with effects that depend on both genetic background and sex.[13]
In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as WIN 55,212-2 are
WIN 55,212-2 is also a
See also
- WIN 48,098(Pravadoline)
- WIN 54,461 (6-Bromopravadoline)
- WIN 55,225(JWH-200)
- WIN 56,098
References
- ^ "Controlled Drugs and Substance Act - Schedule II". Justice Laws Website. Government of Canada. 18 March 2021.
- PMID 18301776.
- PMID 1335057.
- PMID 11459762.
- S2CID 10848076.
- PMID 7565624.
- S2CID 1619608.
- S2CID 33643599.
- PMID 8526880.
- PMID 21615727.
- PMID 8450470.
- PMID 27077495.
- S2CID 25174208.
- ^ : Schedules of controlled substances
- ^ "The Misuse of Drugs Act 1971 (Amendment) Order 2013". legislation.gov.uk.
- S2CID 32450365.
- S2CID 24074568.
Further reading
- Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM (July 2006). "The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin". Proceedings of the National Academy of Sciences of the United States of America. 103 (30): 11393–11398. PMID 16849427.
- Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (February 2005). "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation". The Journal of Neuroscience. 25 (8): 1904–1913. PMID 15728830.
External links
- "Win 55,212-2 Data Sheet". Enzo Life Sciences.